Hypercholesterolemia therapeutics market forecast to show moderate growth

The value of the global hypercholesterolemia therapeutics - cholesterol lowerers - market was put at $29.4 billion in 2010 and is forecast to expand at a compound annual growth rate (CAGR) of 3.9% for the next seven years to reach $38.5 billion by 2017, according to a new report from industry analysts GlobalData.

During historic period (2005-2010) market grew at a CAGR of 3.3%. The hypercholesterolemia therapeutics market is predicted to witness moderate growth by 2017. This is primarily due to the expected launch of two novel therapies, MK-0524A and MK 0524B, from Merck & Co. However in the same forecast period, market will also witness negative impact of the patent expiry of blockbuster products in the coming years like Pfizer’s all-time blockbuster Lipitor (atorvastatin) in the year 2012 followed by Lescol (fluvastatin) and Niaspan (niacin) both in 2013, Pravachol (pravastatin) in 2014 and Crestor (rosuvastatin) in 2016. The approval of Livalo (pitavastatin) in Europe will also positively impact the European hypercholesterolemia therapeutics market.

Strong pipeline with novel therapies